Table 3.
Top canonical pathway analysis of genes significantly impacted in tissue biopsies from HIV-infected individuals.
| Gene symbol | P | Upregulated | Downregulated | Unchanged |
|---|---|---|---|---|
| Altered T-cell and B-cell signaling in rheumatoid arthritis (cellular immune response, disease-specific pathways) |
2.67E–27 | IFNG, IL2, IL6, IL22, IL17A, IL1B, TLR2, TLR4, TLR5, TLR7 |
– | IL10, IL23A, TLR1, TLR8 |
| Role of PRRs in recognition of bacteria and viruses (cellular immune response and pathogen-influenced signaling) |
2.74E–27 | CCL5, IL8, IFNB1, IFNG, IL2, IL6, IL17A, IL1B, TLR2, TLR4, TLR5, TLR7 |
– | IL10, TLR1, TLR8 |
| Communication between innate and adaptive immune cells (cellular Immune response) |
4.43E–27 | CCL5, IL8, IFNB1, IFNG, IL2, IL6, IL1B, TLR2, TLR4, TLR5, TLR7 |
– | IL10, TLR1, TLR8 |
| TREM1 signaling (cellular immune response and cytokine signaling | 6.53E–21 | CCL2, IL8, IL6, IL1B, TLR2, TLR4, TLR5, TLR7 |
– | IL10, TLR1, TLR8 |
| Role of cytokines in mediating communication b/w immune cells (cellular immune response, cytokine signaling, humoral immune response) |
6.12E–20 | IL8, IFNB1, IFNG, IL2, IL6, IL22, IL17A, IL1B |
– | IL10, IL23A |
| Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis (disease-specific pathways) |
1.36E–19 | CCL2, CCL5, IL8, IL6, IL17A, IL1B, IRAK2, TLR2, TLR4, TLR5, TLR7 |
– | IL10, TLR1, TLR8 |
| Role of hypercytokinemia/hyperchemokinemia in the pathogenesis of influenza (disease-specific pathways, pathogen-influenced signaling) |
1.83E–18 | CCL2, CCL5, CCR5, IL8, IFNB1, IFNG, IL6, IL17A, IL1B |
– | – |
| Toll-like receptor signaling (cellular immune response, humoral immune response, pathogen-influenced signaling, apoptosis) |
3.43E–14 | IL1B, IRAK2, TLR2, TLR4, TLR5, TLR7 |
– | TLR1, TLR8 |
| Differential regulation of cytokine production in macrophages and T-helper cells by IL17A & IL17F (cytokine signaling) |
4.73E–14 | CCL2, CCL5, IL6, IL17A, IL1B | – | IL10 |
| Differential regulation of cytokine production in intestinal epithelial cells by IL17A & IL17F (cytokine signaling) |
2.56E–13 | CCL2, CCL5, IFNG, IL17A, IL1B | – | IL10 |
| HMGB1 signaling (cellular immune response, cellular stress and injury, cytokine signaling, humoral immune response) |
1.84E–12 | CCL2, IL8, IFNG, IL2, IL6, IL17A, IL1B, TLR4 |
– | – |
| Hepatic fibrosis/hepatic stellate cell activation (disease-specific pathways, ingenuity toxicity list pathways) |
1.89E–12 | CCL2, CCL5, CCR5, IL8, IFNG, IL6, IL1B, TLR4 |
– | IL10 |
| Hepatic cholestasis (disease-specific pathways, ingenuity toxicity list pathways) |
2.10E–11 | IL8, IFNG, IL2, IL6, IL17A, ILIB, IRAK2, TLR4 |
– | – |
| Glucocorticoid receptor signaling (intracellular and second messenger signaling) |
2.37E–11 | CCL2, CCL5, CD3G, IL8, IFNG, IL2, IL6, IL1B |
– | IL10 |
| Colorectal cancer metastasis signaling (cancer, disease-specific pathways) |
4.24E–10 | IFNG, IL6, TLR2, TLR4, TLR5, TLR7 |
– | TLR1, TLR8 |
| Crosstalk b/w dendritic cells and NK cells (cellular immune response) |
1.39E–09 | IFNB1,IFNG, IL2, IL6, TLR4, TLR7 | – | – |
| NF-KB signaling (cellular immune response, cytokine signaling, humoral immune response, ingenuity toxicity list pathway, organismal growth and development) |
1.81E–09 | IL1B, TLR2, TLR4, TLR5, TLR7 | – | TLR1, TLR8 |
| Dendritic cell maturation (cellular immune response, cytokine signaling, pathogen-influenced signaling) |
2.30E–09 | IFNB1, IL6, ILIB, TLR2, TLR4 | – | IL10, IL23A |
| MSP-RON signaling pathway (cellular immune response) | 3.26E–09 | CCL2, CCR2, IFNG, TLR2, TLR4 | – | – |
| Hematopoiesis from pluripotent stem cells (cellular growth, proliferation and development, organismal growth and development) |
5.57E–09 | CD3G, IL8, IL2, IL6 | – | IL10 |
The Signaling Pathway Categories that each canonical pathway falls under is indicated in parentheses.